| Literature DB >> 27457375 |
Lige Song1, Linuo Zhou2, Zihui Tang3.
Abstract
BACKGROUND: Recent studies have shown that triglyceride (TG), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) are related to the prevalence of cardiovascular autonomic neuropathy (CAN). However, little is known about the association of lipid profile with diabetic cardiovascular autonomic neuropathy (DCAN), or its severity in the Chinese population. The purpose of this study is to explore the extent of this phenomenon using a Chinese sample.Entities:
Keywords: Association; Chinese sample; Diabetic cardiac autonomic neuropathy; Lipid profile
Mesh:
Substances:
Year: 2016 PMID: 27457375 PMCID: PMC4960897 DOI: 10.1186/s12944-016-0287-3
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
The clinical baseline characteristics of individuals
| Variable | Female | Male | Total sample |
|
|---|---|---|---|---|
| Demographic information | ||||
| N | 247 | 208 | 455 | - |
| Age year | 62.17 ± 8.37 | 63.54 ± 8.84 | 62.8 ± 8.61 | 0.016 |
| Height cm | 157.2 ± 5.99 | 167.95 ± 6.33 | 162.12 ± 8.15 | <0.001 |
| Weight kg | 62.9 ± 11.3 | 71.05 ± 10.45 | 66.63 ± 11.65 | <0.001 |
| SBP mmHg | 134.95 ± 21.33 | 133.55 ± 19.02 | 134.3 ± 20.3 | 0.305 |
| DBP mmHg | 81.2 ± 10.1 | 80.93 ± 10.16 | 81.08 ± 10.12 | 0.690 |
| Lipid profile | ||||
| TCmmol/L | 5.64 ± 1.08 | 5.06 ± 1.07 | 5.38 ± 1.11 | <0.001 |
| TG mmol/L | 1.99 ± 1.03 | 1.99 ± 1.34 | 1.99 ± 1.18 | 0.961 |
| HDL mmol/L | 1.38 ± 0.29 | 1.19 ± 0.28 | 1.3 ± 0.31 | <0.001 |
| LDL mmol/L | 3.4 ± 0.86 | 3.14 ± 0.82 | 3.28 ± 0.85 | <0.001 |
| Glucose profile | ||||
| FPG mmol/L | 7.11 ± 2.56 | 7.61 ± 2.82 | 7.34 ± 2.69 | 0.006 |
| PBG mmol/L | 11.9 ± 4.25 | 12.07 ± 4.62 | 11.98 ± 4.42 | 0.583 |
| FINSuIml | 11.09 ± 24.53 | 9.68 ± 24.23 | 10.45 ± 24.39 | 0.388 |
| Renal function | ||||
| SCr μmolL | 73.35 ± 23.1 | 90.93 ± 21.54 | 81.37 ± 24.04 | <0.001 |
| UA μmolL | 280.17 ± 77.45 | 319.48 ± 89.66 | 298.09 ± 85.47 | <0.001 |
| HRV indices | ||||
| HR bpm | 74.96 ± 9.63 | 75.29 ± 11.27 | 75.11 ± 10.41 | 0.634 |
| TP ms2 | 763.34 ± 635.42 | 728.25 ± 734.89 | 747.3 ± 682.53 | 0.440 |
| LF ms2 | 152.57 ± 145.95 | 183.19 ± 293.24 | 166.57 ± 225.93 | 0.042 |
| HF ms2 | 163.58 ± 193.2 | 138.57 ± 182.1 | 152.15 ± 188.51 | 0.046 |
| LF/HF | 1.66 ± 1.91 | 2.05 ± 2.33 | 1.84 ± 2.12 | 0.006 |
| Medical history | ||||
| Smokingyes,% | 4(1.62 %) | 85(40.87 %) | 89(19.56 %) | <0.001 |
| DMD year | 4.86 ± 6.29 | 5.73 ± 6.62 | 5.24 ± 6.45 | 0.063 |
| HTNyes,% | 318(64.37 %) | 264(63.46 %) | 582(63.96 %) | 0.776 |
| HTND year | 5.62 ± 9.05 | 7.41 ± 10.96 | 6.42 ± 9.99 | 0.008 |
| MetSyes,% | 187(75.71 %) | 143(68.75 %) | 330(72.53 %) | 0.019 |
| DCANyes,% | 67(27.13 %) | 65(31.25 %) | 132(29.01 %) | 0.172 |
Note: SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, PBG plasma blood glucose, FINS fasting blood insulin, TC serum total cholesterol, TG triglyceride, HDL high-density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, SCr serum creatinine, HR heart rate, TP total power of variance, LF low frequency, HF high frequency, MetS metabolic syndrome, DMD diabetes duration, HTN Hypertension, HTND Hypertension duration, DCAN diabetic cardiovascular autonomic neuropathy
Fig. 1Comparison of prevalence of diabetic cardiovascular autonomic neuropathy (DCAN) according to serum total cholesterol (TC). a: Comparison of DCAN prevalence according to TC with trinary variables. DCAN prevalence was 27.01 %, 28.87 % and 33.33 % in the three groups, respectively. No significant differences among the three groups were reported (P = 0.452). b: Comparison of DCAN prevalence according to TC with binary variables. DCAN prevalence was 27.76 % and 33.33 % in the two groups, respectively. No significant differences between the two groups were reported (P = 0.122)
Fig. 2Comparison of prevalence of diabetic cardiovascular autonomic neuropathy (DCAN) according to triglyceride (TG). a: Comparison of DCAN prevalence according to TG with trinary variables. DCAN prevalence was 25.34 %, 29.13 % and 35.25 % in the three groups, respectively. A significant differences among the three groups were reported (P =0.022 and P for trend = 0.006). b: Comparison of DCAN prevalence according to TG with binary variables. DCAN prevalence was 26.54 % and 35.25 % in the two groups, respectively. A significant differences between the two groups were reported (P = 0.010)
Fig. 3Comparison of prevalence of diabetic cardiovascular autonomic neuropathy (DCAN) according tolow density lipoprotein cholesterol (LDL). a: Comparison of DCAN prevalence according to LDL with trinary variables. DCAN prevalence was 28.40 %,28.13 % and 32.86 % in the three groups, respectively. No significant differences among the three groups were reported (P =0.622). b: Comparison of DCAN prevalence according to LDL with binary variables. DCAN prevalence was 28.31 % and 32.86 % in the two groups, respectively. A significant differences between the two groups were reported (P = 0.276)
Fig. 4Comparison of prevalence of diabetic cardiovascular autonomic neuropathy (DCAN) according tohigh-density lipoprotein cholesterol (HDL). Comparison of DCAN prevalence according to HDL. DCAN prevalence was 28.89%n and 29.47 % in the two groups, respectively. There were no significant differences between the two groups (P = 0.371)
Univariate analysis to include independent variables for diabetic cardiovascular autonomic neuropathy
| Variable |
| SE |
| OR | 95 % CI |
|---|---|---|---|---|---|
| Lipid profile | |||||
| TC mmol/L | 0.067 | 0.065 | 0.308 | 1.069 | 0.94–1.215 |
| TG mmol/L | 0.257 | 0.06 | <0.001 | 1.293 | 1.15–1.455 |
| HDL mmol/L | −0.231 | 0.243 | 0.340 | 0.793 | 0.493–1.277 |
| LDL mmol/L | −0.040 | 0.086 | 0.645 | 0.961 | 0.811–1.138 |
| Covariance | |||||
| Age years | 0.035 | 0.009 | <0.001 | 1.036 | 1.018–1.054 |
| Gender male | 0.200 | 0.146 | 0.172 | 1.221 | 0.917–1.627 |
| BMI kg/cm2 | 0.029 | 0.012 | 0.043 | 1.03 | 1.01–1.07 |
| SBP mmHg | 0.004 | 0.004 | 0.242 | 1.004 | 0.997–1.011 |
| DBP mmHg | 0.002 | 0.007 | 0.806 | 1.002 | 0.988–1.016 |
| FPG mmol/L | 0.098 | 0.026 | <0.001 | 1.103 | 1.048–1.161 |
| PBG mmol/L | 0.081 | 0.017 | <0.001 | 1.084 | 1.049–1.121 |
| FINS uml | 0.006 | 0.003 | 0.031 | 1.006 | 1.001–1.012 |
| SCr μmolL | 0.005 | 0.003 | 0.073 | 1.005 | 1.00–1.011 |
| HR bpm | 0.091 | 0.009 | <0.001 | 1.095 | 1.076–1.114 |
| Smoking yes | 0.210 | 0.18 | 0.242 | 1.234 | 0.868–1.756 |
| DMD years | 0.031 | 0.012 | 0.010 | 1.031 | 1.007–1.056 |
| HTN yes | 0.120 | 0.153 | 0.433 | 1.128 | 0.835–1.523 |
| HTND years | 0.014 | 0.007 | 0.050 | 1.014 | 1.00–1.028 |
| MetS yes | 0.527 | 0.175 | 0.003 | 1.694 | 1.202–2.387 |
Note: SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, PBG plasma blood glucose, FINS fasting blood insulin, TC serum total cholesterol, TG triglyceride, HDL high-density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, SCr serum creatinine, HR heart rate, MetS metabolic syndrome, HTN Hypertension
Association analysis between lipid profile for diabetic cardiovascular autonomic neuropathy using multiple variable logistic regression analysis
| Model | Variable | β | SE |
| OR | 95 % CI |
|---|---|---|---|---|---|---|
| Model 1 | ||||||
| TC | 0.273 | 0.265 | 0.304 | 1.313 | 0.781–2.208 | |
| TG | 0.223 | 0.106 | 0.036 | 1.25 | 1.015–1.54 | |
| LDL | −0.454 | 0.304 | 0.136 | 0.635 | 0.35–1.154 | |
| HDL | 0.545 | 0.380 | 0.151 | 1.725 | 0.819–3.631 | |
| Model 2 | ||||||
| TC | 0.130 | 0.322 | 0.686 | 1.139 | 0.606–2.139 | |
| TG | 0.355 | 0.213 | 0.096 | 1.427 | 0.939–2.167 | |
| LDL | 0.031 | 0.337 | 0.928 | 1.031 | 0.533–1.996 | |
| HDL | 0.358 | 0.250 | 0.152 | 1.430 | 0.876–2.336 |
Note: Model 1: lipid profiles with continuous variable, Model 2: lipid profiles with binary variable
TC serum total cholesterol, TG triglyceride, LDL low density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, BMI body mass index; all models adjusted for age, gender, smoking, BMI, blood pressure, glucose profile, renal function, medical history
Fig. 5Comparison of prevalence of diabetic cardiovascular autonomic neuropathy (DCAN) according to lipid profile risk score (LRS). a: Comparison of DCAN prevalence according to LRS-1. DCAN prevalence was 25.48 %, 32.70 % and 37.84 % in the three groups, respectively. There were significant differences among the three groups (P for difference = 0.018 and P for a trend =0.005). b: Comparison of DCAN prevalence according to LRS-2. DCAN prevalence was 26.18 %, 32.08 % and 42.86 % in the four groups, respectively. There were significant differences among the three groups (P for difference = 0.024 and P for a trend =0.007). c: Comparison of DCAN prevalence according to LRS-3. DCAN prevalence was 27.14 %,30.14 % and 37.50 % in the three groups, respectively. There were no significant differences among the three groups (P for difference = 0.140 and P for a trend =0.059). d: Comparison of DCAN prevalence according to LRS-4. DCAN prevalence was 28.14 %, 30.32 % and 40.00 % in the three groups, respectively. There were no significant differences among the four groups (P for difference =0.548 and P for a trend =0.363)
The association analysis of severity of lipid profile and diabetic cardiovascular autonomic neuropathy using multiple variable logistic regression analysis
| Model | Variable | β | SE |
| OR | 95 % CI |
|---|---|---|---|---|---|---|
| Model 1 | ||||||
| LRS-1 | 0.291 | 0.153 | 0.058 | 1.337 | 0.99–1.806 | |
| Model 2 | ||||||
| LRS-2 | 0.278 | 0.158 | 0.079 | 1.321 | 0.968–1.801 | |
| Model 3 | ||||||
| LRS-3 | 0.055 | 0.155 | 0.722 | 1.057 | 0.78–1.431 | |
| Model 4 | ||||||
| LRS-4 | −0.077 | 0.186 | 0.680 | 0.926 | 0.644–1.333 |
Note: Model 1: LRS-1 (lipid profile risk score) derived from TC and TG, Model 2: LRS-2 (lipid profile risk score) derived from TG and LDL, Model 3: LRS-3 (lipid profile risk score) derived from TG and HDL, Model 4: LRS-4 (lipid profile risk score) derived from LDL and HDL; BMI-body mass index; all models adjusted for age, gender, smoking, BMI, blood pressure, glucose profile, renal function, medical history